Keyphrases
Acinetobacter Baumannii (A. baumannii)
17%
Antibiotic Resistance
18%
Antibiotics
25%
Antimicrobial
14%
Antimicrobial Resistance
25%
Bacteremia
23%
Baumannii
14%
Bloodstream Infection
50%
Carbapenem Resistance
25%
Carbapenem-resistant Acinetobacter Baumannii
47%
Carbapenem-resistant Enterobacteriaceae
31%
Carbapenemase
18%
Carbapenemase-producing
18%
Carbapenemase-producing Enterobacterales
27%
Carbapenems
28%
Ceftazidime
17%
Cephalosporins
15%
Ciprofloxacin
15%
Clostridioides Difficile
15%
Colistin
27%
Confidence Interval
27%
CTX-M
13%
Enterobacteriaceae
52%
Epidemiology
15%
Ertapenem
19%
Escherichia Coli
36%
Europe
21%
Extended-spectrum-lactamase
55%
Hospitalized Patients
22%
Imipenem
26%
Infection Control
18%
Israel
100%
Israeli
33%
Klebsiella Pneumoniae (K. pneumoniae)
53%
Klebsiella Pneumoniae Carbapenemase
35%
KPC-2
23%
KPC-producing Klebsiella Pneumoniae
16%
Lactams
14%
Medical Center
13%
Methicillin-resistant Staphylococcus Aureus
33%
Multidrug-resistant Pseudomonas Aeruginosa (MDRPA)
24%
Odds Ratio
23%
Plasmid
29%
Pseudomonas Aeruginosa (P. aeruginosa)
38%
Risk Factors
41%
Staphylococcus Aureus
15%
Tel Aviv
16%
Vancomycin
15%
Vancomycin-resistant Enterococci
17%
β-lactamase
18%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter Baumannii
20%
Acinetobacter Infection
7%
Antibiotic Agent
26%
Antibiotic Resistance
12%
Antibiotics
45%
Antiinfective Agent
20%
Antimicrobial Resistance
10%
Antimicrobial Therapy
8%
Avibactam Plus Ceftazidime
9%
Bacteremia
27%
Bloodstream Infection
32%
Carbapenem
71%
Carbapenem Derivative
14%
Carbapenem Resistant Enterobacteriaceae
20%
Carbapenemase
26%
Carbapenemase Producing Enterobacteriaceae
12%
Case-Control Study
9%
Ceftazidime
12%
Cephalosporin
7%
Cephalosporin Derivative
13%
Ciprofloxacin
8%
Clostridium Difficile Infection
10%
Cohort Study
15%
Colistimethate
23%
Combination Therapy
10%
Disease
11%
Enterobacteriaceae
28%
Ertapenem
11%
Escherichia coli
29%
Extended Spectrum Beta Lactamase
30%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
11%
Gram Negative Bacterium
21%
Imipenem
27%
Infection
74%
Infectious Agent
21%
Klebsiella pneumoniae
36%
Lactam
11%
Meropenem
12%
Methicillin-Resistant Staphylococcus Aureus
11%
Meticillin
9%
Penicillinase
39%
Piperacillin Plus Tazobactam
8%
Prevalence
14%
Pseudomonas aeruginosa
42%
Quinolone Derivative
11%
Randomized Controlled Trial
8%
Staphylococcus Aureus
16%
Surgical Infection
7%
Vancomycin
9%
Wound Infection
7%
Medicine and Dentistry
Acinetobacter Baumannii
24%
Antibiogram
8%
Antibiotic Resistance
21%
Antibiotic Therapy
6%
Antibiotics
38%
Antiinfective Agent
19%
Avibactam Plus Ceftazidime
8%
Bacteremia
16%
Bloodstream Infection
28%
Carbapenem
43%
Carbapenem Derivative
11%
Carbapenem-Resistant Enterobacteriaceae
23%
Carbapenemase
21%
Carbapenemase Producing Enterobacteriaceae
15%
Ceftazidime
8%
Cephalosporin
6%
Ciprofloxacin
6%
Clostridium Difficile Infection
11%
Cohort Analysis
12%
Cohort Effect
15%
Colistimethate
11%
Enterobacter
7%
Enterobacteriaceae
35%
Ertapenem
14%
Escherichia coli
15%
Extended Spectrum Beta Lactamase
26%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
20%
Gram-Negative Bacteria
15%
Imipenem
11%
Infection
51%
Infection Control
16%
Intensive Care Unit
11%
Klebsiella pneumoniae
28%
Meropenem
7%
Methicillin Resistant Staphylococcus Aureus
9%
Metronidazole
6%
Neonatal Intensive Care Unit
6%
Odds Ratio
14%
Pathogen
14%
Penicillinase
39%
Peptoclostridium difficile
9%
Piperacillin/Tazobactam
8%
Prevalence
10%
Pseudomonas aeruginosa
20%
Public Health
7%
Randomized Controlled Trial
7%
Rehabilitation Center
8%
Staphylococcus Aureus
12%
Systematic Review
10%
Vancomycin Resistant Enterococcus
9%